日本の再生医療市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Regenerative Medicine Market in Japan 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Healthcare reforms in Japan

PART 06: Regulatory landscape in Japan
• ASRM
• PMD Act

PART 07: Reimbursement scenario
• Reimbursement scenario for regenerative medicine in Japan

PART 08: Gene therapy: An emerging field in regenerative medicine

PART 09: Pipeline portfolio

PART 10: Market landscape
• Market overview
• Five forces analysis

PART 11: Market segmentation by product
• Cell therapy
• Cell therapy regenerative medicine market in Japan
• Tissue scaffold
• Tissue scaffold regenerative medicine market in Japan

PART 12: Market segmentation by application
• Dermatology
• Musculoskeletal
• Cardiovascular
• Other

PART 13: Market drivers
• Transformation of regulatory landscape fostering quick approval of regenerative medicines
• Growing partnerships of MNCs with local vendors in Japan
• Recent product approvals fuel the market growth
• Government initiatives driving regenerative medicine market in Japan

PART 14: Impact of drivers

PART 15: Market challenges
• Ethical challenges involved in regenerative medicine
• High cost and failure rate in clinical trials coupled with inadequate clinical evidence
• Low competitive edge of Japanese regenerative medicine market over other developed nations

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Strong pipeline portfolio of regenerative medicines
• Entry of new players expanding the applications of regenerative medicine
• Strategic collaborations and acquisitions
• Advent of 3D tissue bioprinters for the development of regenerative medicines

PART 18: Vendor landscape
• Competitive scenario
• Key news
• Product approvals
• Partnerships
• Mergers and acquisitions
• Other

PART 19: Key vendor analysis
• CellSeed
• JCR Pharmaceuticals
• Japan Tissue Engineering (J-TEC)
• Terumo
• Upcoming vendors
• Other prominent vendors

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Regenerative medicine application in various therapeutics
Exhibit 03: Major applications of regenerative medicine in Japan
Exhibit 04: Regenerative medicine legislation acts in Japan
Exhibit 05: Product approval and regulatory characteristics in Japan
Exhibit 06: Overview of regenerative medicine regulation acts
Exhibit 07: Landscape of regenerative medicine in Japan
Exhibit 08: Risk categories of regenerative medical technologies
Exhibit 09: Regenerative medicine approval process in Japan under the ASRM
Exhibit 10: Regenerative medicine approval process in Japan under PMD Act
Exhibit 11: Comparison of traditional and new product approval process under the PMD Act
Exhibit 12: Conditional approvals for regenerative medical products versus regular approval for pharmaceuticals
Exhibit 13: Japan’s NHI pricing methods
Exhibit 14: NHI pricing calculation for TEMCELL HS
Exhibit 15: NHI pricing calculation for HeartSheet A kit
Exhibit 16: NHI pricing calculation for HeartSheet B kit
Exhibit 17: Gene therapy research by sponsorship
Exhibit 18: Regenerative medicine pipeline products in Japan
Exhibit 19: Pipeline analysis of regenerative medicine in Japan 2015
Exhibit 20: Pipeline products of regenerative medicine for cell therapy in 2015
Exhibit 21: Key developments in regenerative medicine market in Japan 2015
Exhibit 22: Regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 23: Regenerative medicine market in Japan: Optimistic and pessimistic analyses 2015-2020
Exhibit 24: Optimistic and pessimistic market analysis of regenerative medicine in Japan 2015-2020
Exhibit 25: Five forces analysis
Exhibit 26: Regenerative medicine market in Japan by product 2015 and 2020
Exhibit 27: Positioning of segments (by product type) in regenerative medicine market in Japan 2015
Exhibit 28: Regenerative medicine market in Japan: Lifecycle analysis by product 2015
Exhibit 29: Cell therapy overview
Exhibit 30: Ethical issues involved in different cell therapy research category
Exhibit 31: Stem cell research policies in Japan
Exhibit 32: Key cell therapy products marketed in Japan
Exhibit 33: Cell therapy regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 34: Opportunity analysis of cell therapy regenerative medicine market in Japan
Exhibit 35: Collaborations for R&D of tissue scaffold
Exhibit 36: Tissue scaffold regenerative medicine market in Japan 2015-2020 ($ millions)
Exhibit 37: Opportunity analysis of tissue scaffold in Japan regenerative medicine market
Exhibit 38: Regenerative medicine market in Japan by product type 2015-2020 ($ millions)
Exhibit 39: Regenerative medicine market in Japan 2015-2020 (%)
Exhibit 40: Overview of the regenerative medicine dermatology market in Japan
Exhibit 41: Pipeline of regenerative medicine for dermatology
Exhibit 42: Overview of musculoskeletal regenerative medicine market in Japan
Exhibit 43: Overview of cardiovascular regenerative medicine market in Japan
Exhibit 44: Regulatory guidelines in Japan
Exhibit 45: Approval process of SAKIGAKE assignment system
Exhibit 46: Partnerships of MNCs with local vendors in Japan
Exhibit 47: MHLW budget on drug discovery using iPS cells ($ millions)
Exhibit 48: Impact of drivers
Exhibit 49: Force field analysis of regenerative medicine market in Japan
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Regenerative medicine pipeline portfolio 2015
Exhibit 52: Current applications of regenerative medicine
Exhibit 53: Future applications of regenerative medicine
Exhibit 54: Major strategic collaborations and acquisitions in Japan
Exhibit 55: Impact of trends in regenerative medicine in Japan 2015-2020
Exhibit 56: Presence of vendors in regenerative medicine
Exhibit 57: CellSeed: Profile
Exhibit 58: CellSeed: Strength analysis
Exhibit 59: CellSeed: Growth strategy matrix
Exhibit 60: CellSeed: Opportunity assessment
Exhibit 61: JCR Pharmaceuticals: Profile
Exhibit 62: JCR Pharmaceuticals: Strength analysis
Exhibit 63: JCR Pharmaceuticals: Growth strategy matrix
Exhibit 64: JCR Pharmaceuticals: Opportunity assessment
Exhibit 65: J-TEC: Profile
Exhibit 66: J-TEC: Strength analysis
Exhibit 67: J-TEC: Growth strategy matrix
Exhibit 68: J-TEC: Opportunity assessment
Exhibit 69: Terumo: Profile
Exhibit 70: Terumo: Strength analysis
Exhibit 71: Terumo: Growth strategy matrix
Exhibit 72: Terumo: Opportunity assessment


【レポート販売概要】

■ タイトル:日本の再生医療市場2016-2020
■ 英文:Regenerative Medicine Market in Japan 2016-2020
■ 発行日:2016年9月28日
■ 調査会社:Technavio
■ 商品コード:IRTNTR10337
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。